Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

APTO

Aptose Biosciences Inc

Dec 12 • 04:00PM ET

0.1925

Dollar change +0.0086
Percentage change 4.68	%

Healthcare • Biotechnology • Canada • NASD

Peers: ARGX BCRX AGEN FATE CARA AFMD BLUE DTIL CRBP

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.05	Insider Own	6.17%	Shs Outstand	59.52M	Perf Week	-0.72%
Market Cap	11.46M	Forward P/E	-	EPS next Y	-	Insider Trans	2.80%	Shs Float	55.85M	Perf Month	-50.76%
Income	-35.80M	PEG	-	EPS next Q	-0.35	Inst Own	5.43%	Short Float	0.18%	Perf Quarter	-48.49%
Sales	0.00M	P/S	-	EPS this Y	76.39%	Inst Trans	121.89%	Short Ratio	0.22	Perf Half Y	-79.30%
Book/sh	-0.47	P/B	-	EPS next Y	-	ROA	-225.12%	Short Interest	0.10M	Perf Year	-92.11%
Cash/sh	0.13	P/C	1.44	EPS next 5Y	-	ROE	-694.13%	52W Range	0.13 - 2.71	Perf YTD	-92.42%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.18%	ROI	-3057.22%	52W High	-92.90%	Beta	0.94
Dividend TTM	-	Quick Ratio	1.05	Sales past 5Y	0.00%	Gross Margin	-	52W Low	48.08%	ATR (14)	0.03
Dividend Ex-Date	-	Current Ratio	1.05	EPS Y/Y TTM	61.28%	Oper. Margin	-	RSI (14)	29.68	Volatility	10.62% 13.26%
Employees	35	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	2.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	78.74%	Payout	-	Rel Volume	2.58	Prev Close	0.18
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Nov 08 AMC	Avg Volume	459.83K	Price	0.19
SMA20	-16.30%	SMA50	-39.80%	SMA200	-75.02%	Trades		Volume	1,184,132	Change	4.68%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-19-20	Initiated	Cantor Fitzgerald	Overweight	$10
Sep-22-20	Initiated	Alliance Global Partners	Buy	$12
Feb-20-20	Initiated	Maxim Group	Buy	$16
Feb-06-20	Reiterated	H.C. Wainwright	Buy	$6 → $9
Jan-09-20	Initiated	Piper Sandler	Overweight	$10
Mar-01-19	Initiated	RBC Capital Mkts	Outperform	$6
Nov-16-18	Initiated	B. Riley FBR	Buy	$5
Dec-13-17	Reiterated	H.C. Wainwright	Buy
Oct-23-17	Resumed	ROTH Capital	Buy	$5
Sep-07-17	Upgrade	H.C. Wainwright	Neutral → Buy	$1 → $4
Jun-08-17	Initiated	Rodman & Renshaw	Neutral	$1

Show Previous Ratings

Dec-12-24 10:15AM	Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax (GlobeNewswire)
Dec-09-24 12:00PM	Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML (GlobeNewswire)
Dec-03-24 07:30AM	Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials (GlobeNewswire)
Nov-25-24 04:15PM	Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering (GlobeNewswire)
Nov-22-24 04:00PM	S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results (Benzinga) -22.13%
08:00AM	Loading…
08:00AM	Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering (GlobeNewswire)
Nov-20-24 07:30AM	Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy (GlobeNewswire) -23.97%
Nov-08-24 04:01PM	Aptose Reports Results for the Third Quarter 2024 (GlobeNewswire)
Sep-05-24 04:15PM	Aptose Announces Results from Special Meeting of Shareholders (GlobeNewswire)
Sep-02-24 04:12AM	Aptose Biosciences secures funds for AML treatment development (Pharmaceutical Technology)
Aug-30-24 04:30PM	Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib (GlobeNewswire)
Aug-15-24 04:30PM	Aptose Announces Adjournment of its Special Meeting of Shareholders (GlobeNewswire)
Aug-08-24 06:07PM	Aptose Biosciences: Q2 Earnings Snapshot (Associated Press Finance) +11.22% -7.53%
05:06PM	Aptose Reports Results for the Second Quarter 2024 (GlobeNewswire)
Aug-01-24 07:00AM	NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer (GlobeNewswire) -7.71%
05:00PM	Loading…
Jul-19-24 05:00PM	Aptose Announces Receipt of Deficiency Notice from Nasdaq (GlobeNewswire) -6.15%
Jun-18-24 05:30PM	Aptose Announces Results from Annual and Special Meeting of Shareholders (GlobeNewswire)
Jun-14-24 07:30AM	Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress (GlobeNewswire)
Jun-13-24 12:00PM	Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jun-03-24 04:30PM	Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
May-31-24 08:00AM	Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -15.95%
May-14-24 09:54PM	APTO Stock Earnings: Aptose Biosciences Beats EPS for Q1 2024 (InvestorPlace)
04:32PM	Aptose Biosciences Q1 Net Loss Falls, on Lower Expenses (MT Newswires)
04:21PM	Aptose Biosciences: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Aptose Reports Results for the First Quarter 2024 (GlobeNewswire)
May-06-24 04:30PM	Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 (GlobeNewswire)
Apr-05-24 12:00PM	What Makes Aptose Biosciences (APTO) a New Buy Stock (Zacks)
Mar-27-24 08:26AM	Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript (Insider Monkey) -6.25%
Mar-26-24 08:53PM	APTO Stock Earnings: Aptose Biosciences Beats EPS for Q4 2023 (InvestorPlace) +5.96%
04:01PM	Aptose Reports Results for the Fourth Quarter and Full Year 2023 (GlobeNewswire)
04:30PM	Loading…
Mar-18-24 04:30PM	Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024 (GlobeNewswire)
Jan-31-24 04:01PM	Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option (GlobeNewswire)
Jan-26-24 08:36AM	Why Is Aptose Biosciences (APTO) Stock Down Today? (InvestorPlace)
08:00AM	Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical (GlobeNewswire)
Dec-09-23 06:30PM	Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting (GlobeNewswire)
Nov-30-23 04:59PM	Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role (GlobeNewswire) -9.29% +9.02%
Nov-10-23 11:21AM	Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call Transcript (Insider Monkey) -24.38%
Nov-09-23 04:17PM	Aptose Biosciences: Q3 Earnings Snapshot (Associated Press Finance) +5.88%
04:00PM	Aptose Reports Results for the Third Quarter 2023 (GlobeNewswire)
Nov-02-23 09:00AM	Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting (GlobeNewswire)
Oct-30-23 09:15AM	Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib (GlobeNewswire) -13.52%
Oct-26-23 07:11AM	Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023 (GlobeNewswire) +9.30%
Oct-23-23 07:30AM	Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th (GlobeNewswire)
Oct-16-23 07:30AM	Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference (GlobeNewswire) +30.84%
Sep-18-23 07:45AM	Aptose to Present at the Cantor Global Healthcare Conference (GlobeNewswire) +5.17%
Sep-06-23 07:45AM	Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical (GlobeNewswire) -6.19%
Aug-24-23 07:30AM	Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 04:08PM	Aptose Biosciences: Q2 Earnings Snapshot (Associated Press Finance) +6.38% +8.75%
04:02PM	Aptose Reports Results for the Second Quarter 2023 (GlobeNewswire)
Jul-27-23 04:04PM	Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023 (GlobeNewswire)
Jun-26-23 04:05PM	Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance (GlobeNewswire) -5.99%
Jun-10-23 12:00PM	Aptose Presents Highlights from Clinical Update (GlobeNewswire)
Jun-05-23 07:30AM	Aptose Biosciences Provides Update on Reverse Stock Split (GlobeNewswire)
May-31-23 07:30AM	Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023 (GlobeNewswire)
May-25-23 04:14PM	Aptose Enters into $25 Million Committed Equity Facility (GlobeNewswire) -6.37%
May-23-23 05:30PM	Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders (GlobeNewswire) -7.98%
May-21-23 10:03AM	3 Stocks With 1,000% Upside Potential (InvestorPlace)
May-11-23 07:28AM	Aptose Biosciences Inc.'s (TSE:APS) Path To Profitability (Simply Wall St.)
May-08-23 04:13PM	Aptose Biosciences: Q1 Earnings Snapshot (AP Finance)
04:01PM	Aptose Reports Results for the First Quarter 2023 (GlobeNewswire)
May-04-23 07:01AM	Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference (GlobeNewswire)
Apr-24-23 07:01AM	Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023 (GlobeNewswire)
Apr-10-23 04:01PM	Aptose to Participate in Canaccord Genuitys 2023 Horizons in Oncology Virtual Conference (GlobeNewswire)
Mar-28-23 04:01PM	Aptose Biosciences to Participate in Cantors The Future of Oncology Virtual Symposium (GlobeNewswire)
09:40AM	Are Medical Stocks Lagging Annovis Bio (ANVS) This Year? (Zacks)
Mar-27-23 08:45AM	Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-23-23 04:44PM	Aptose Reports Results for the Fourth Quarter and Full Year 2022 (GlobeNewswire) +12.98%
Mar-10-23 06:44PM	Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank (GlobeNewswire) -5.33%
Mar-09-23 04:05PM	Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023 (GlobeNewswire)
Mar-02-23 07:30AM	Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Jan-30-23 07:00AM	Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia (GlobeNewswire)
Dec-30-22 08:02AM	We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully (Simply Wall St.) +7.61%
Dec-28-22 07:30AM	Aptose Biosciences to Present at Biotech Showcase 2023 Conference (GlobeNewswire) +7.77%
Dec-12-22 06:15AM	Aptose Biosciences Establishes New At-The-Market Facility (GlobeNewswire)
Dec-11-22 09:00AM	Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations (GlobeNewswire)
Dec-07-22 04:05PM	Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th (GlobeNewswire)
Nov-14-22 07:30AM	Aptose Treats First Patient with Continuous Dosing of New G3 Formulation of Luxeptinib (GlobeNewswire)
Nov-03-22 09:10AM	Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting (GlobeNewswire) +30.55%
Nov-01-22 04:01PM	Aptose Reports Results for the Third Quarter 2022 (GlobeNewswire) +8.32% +10.26%
Oct-18-22 04:01PM	Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022 (GlobeNewswire) -6.03%
Sep-30-22 08:59AM	Horizon (HZNP) Completes Enrollment in Phase IV TED Study (Zacks)
Sep-29-22 11:09AM	Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis (Zacks)
Sep-28-22 01:47PM	Merck's (MRK) Keytruda Gets Four New Approvals in Japan (Zacks) +6.45%
Sep-27-22 11:44AM	Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223 (Zacks)
10:13AM	Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral (Zacks)
Sep-21-22 06:32PM	Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod (Zacks)
Sep-20-22 09:49AM	Seagen's (SGEN) Tukysa Gets FDA Priority Review for New Indication (Zacks)
Sep-19-22 12:28PM	Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe (Zacks)
Sep-14-22 07:30AM	Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference (GlobeNewswire)
Sep-13-22 03:45PM	Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal (Zacks)
08:44AM	Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review (Zacks)
07:30AM	Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D. (GlobeNewswire)
Sep-12-22 07:30AM	Aptoses New G3 Formulation of Luxeptinib Boosts Bioavailability (GlobeNewswire)
Aug-30-22 07:30AM	Aptose to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-02-22 04:01PM	Aptose Reports Results for the Second Quarter 2022 (GlobeNewswire) +8.46%
Jul-27-22 07:30AM	Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference (GlobeNewswire)
Jul-23-22 08:08AM	Is Aptose Biosciences (TSE:APS) In A Good Position To Invest In Growth? (Simply Wall St.)
Jul-19-22 04:01PM	Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022 (GlobeNewswire)
Jun-27-22 07:30AM	Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer (GlobeNewswire)
Jun-02-22 08:10PM	CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event (GlobeNewswire) -5.52%

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rice William G.	Chair, President & CEO	Nov 25 '24	Buy	0.20	100,000	20,000	613,252	Nov 26 06:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APTO

Aptose Biosciences Inc

Upgrade your FINVIZ experience